Change from baseline
Concentration (nM) % % % mV % mV % % EADs N 10 2.9 ± 1.1 6.7 ± 0.8* 8.8 ± 0.5* 0.2 ± 0.5 -0.3 ± 0.6 -0.1 ± 0.4 3.4 ± 3.0 23.4 ± 16.9 0/3 3 30 9.2 ± 0.9* 23.5 ± 2.1* 32.5 ± 3.5* 2.2 ± 0.5* -2.6 ± 1.6 -0.7 ± 2.0 -2.1 ± 4.7 55.5 ± 19.8 0/3 3 100 13.2 ± 2.9* 56.9 ± 1.9* 110.6 ± 1.7* 3.9 ± 1.2 -5.2 ± 1.0* -2.2 ± 1.8 -25.6 ± 5.5 94. 2.7 ± 0.3* 5.5 ± 0.8* 6.8 ± 0.9* 0.6 ± 0.4 -0.6 ± 0.4 0 ± 1.2 -7.3 ± 4.7 3.3 ± 0.8 0/5 5 100 11.4 ± 1.1* 24.6 ± 2.5* 31.1 ± 2.8* 1.4 ± 0.3* -1.7 ± 0.6 -1.7 ± 1.2 -10.6 ± 5.8 7.8 ± 6.0 0/5 5 300 19.8 ± 5.8* 52.5 ± 1.6* 90.9 ± 3.7* 6.8 ± 0.9* -8.5 ± 3.3* -8.7 ± 9.0 -54. 
30
-5.8 ± 1.0* -5.3 ± 0.6* -4.3 ± 0.5* -0.1 ± 0.5 -3.3 ± 1.1 -4.0 ± 1.1 -6.9 ± 2.4 2.4 ± 2.4 0/3 3 100 -31.4 ± 2.4* -27.0 ± 1.1* -22.3 ± 1.1* 0.9 ± 1.0 -7.7 ± 3.1 -8.3 ± 2.7 -8.3 ± 3.1 -16.4 ± 1.5* 0/3 3 300 -53.2 ± 5.6* -43.3 ± 2.5* -33.5 ±1.9* 1.1 ± 1.1 -11.8 ± 4.4 -12.8 ± 4.7 -9.3 ± 3.3* -28.0 ± 1.1* 0/3 3 1000 -69.1 ± 6.7* -50.1 ± 2.9* -27.4 ±1.7* 2.8 ± 1.0 -18.1 ± 6.3 -18.5 ± 6.6 -18.4 ± 4.2* -23.5 ± 3.3* 0/3 3 APDs 30, 60 and 90 indicates duration of the action potential from the point of maximal dV/dt in the upstroke to 30%, 60% and 90% repolarization; MDP: maximal diastolic potential; APA: action potential amplitude; Overshoot: maximal depolarization; Vmax: maximal depolarization rate (dV/dt) during the upstroke of the action potential; Period: time between two action potentials. EADs: early after depolarization. The ratio indicates the fraction of cells showing EADs. N: number of cells. NM: not measured due to the presence of arrhythmias. Asterisks indicate significant difference with respect to baseline at p < 0.05. 
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Supplementary Figure 2. Concentration response curves for vanoxerine, bepridil, dofetilide and verapamil
Symbols indicate the mean ± sem and the number of associated experiments. The data was obtained using step-ramps except for hNav1.5 late currents in verapamil where the voltage protocol consisted of a 200 ms pulse to -120 mM, a 5 ms pulse to +50 mV followed by a 400 ms pulse to -30 mV. S 6.1 summarizes the effects of vanoxerine and dofetilide on APD90 of epicardial action potentials recorded in the canine wedge preparation. Data are from Table 4 in Lacerda et al. 2 .The percent changes from control were fitted to a logistic function with half maximum effect (APD90 half ) at 206 nM for vanoxerine and 18.2 nM for dofetilide. APD prolongation at APD90 half was 3.05% and 11.1% respectively. These values are indicated by vertical lines in the figure.
Supplementary
The maximum responses to vanoxerine and dofetilide were 6.1 and 22.6% respectively. Symbols are mean ± sem.
S 6.1
We hypothesized that the limited effects in situ are due to tissue binding similar to the binding of the drug to plasma proteins in equilibrium dialysis 1 . To estimate the amount of non-specific tissue binding in the wedge experiments we used in silico simulations of the Decker-Rudy model of the canine epicardial action potential 2 .
We investigated the effect of stepwise reductions in the vanoxerine concentration from the simulated APD90 shortening at 206 nM free vanoxerine showing a small attenuated AP not at all like a CAP (blue line in S 6.2c) to the experimentally observed prolongation of 3.05 % at APD90 half . We took as a measure of non-specific (NS) binding the factor that reduces the free concentration from APD90 half to a level that produced 3.05% prolongation. Non-specific tissue binding for vanoxerine was calculated at 99.8% consistent with the strong binding measured with the equilibrium dialysis method. Non-specific binding reduced the total drug concentration from 206 nM to an unbound concentration of 0.5 nM. At that free concentration the shape of the simulated action potential (red line in S 6.2c) is comparable to the action potential recorded in the wedge preparation (S 6.2a).
We used the same approach to assess non-specific binding of dofetilide in the wedge preparation. The model predicts that in the absence of non-specific binding 18.2 nM, the APD90 half for dofetilide, should elicit arrhythmic activity (blue line in S 6.2d). However, 89.4% non-specific binding reduced the free concentration from 18.2 nM to 1.94 nM, a concentration that that produced an 11.1% change in APD90. The shape of the simulated action potential is comparable to the shape of the action potential recorded in the wedge preparation (red line in S 6.2d). The measured 89.4% non-specific binding for dofetilide is close to the 60-70% range that is reported (http://dailymed.nlm.nih.gov/dailymed). Table 1 in the text. Black lines: no drug; blue lines: simulation based on APD90 half (Note the lack of concordance with the experiments in a and b); red lines: action potential waveforms calculated assuming 99.8% and 89.4% non-specific binding for vanoxerine and dofetilide respectively. Action potentials were simulated using the Decker-Rudy cardiac epicardial dog model 3 .
Simulations used the conductance-block approach where maximal conductances were modified according to the measured IC50s and Hill coefficients ( Table 1) . Two thousand action potentials were simulated to ensure attainment of steady state.
